



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Statement of Unaudited Financial Results for the Quarter and Six Months ended 30.09.2012 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
		30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	50582.52	40413.21	29937.20	90995.73	51844.57	134173.78
	Less : Excise Duty	1108.49	1058.21	910.70	2166.70	1937.53	3845.02
	Net Sales	49474.03	39355.00	29026.50	88829.03	49907.04	130328.76
	(b) Other Operating Income	52.77	61.85	238.55	114.62	479.13	981.84
	Total Income from Operations (net)	49526.80	39416.85	29265.05	88943.65	50386.17	131310.60
2.	Expenses						
	(a) Cost of Materials consumed	36940.47	24266.62	18940.96	61207.09	37951.96	99060.46
	(b) Purchase of Stock in Trade	990.62	3499.86	1636.77	4490.48	2771.57	6302.74
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(331.98)	1481.01	(444.93)	1149.03	(7328.29)	(13466.91)
	(d) Employee benefits expense	1149.93	1075.06	1234.39	2224.99	2474.74	4765.86
	(e) Depreciation and amortisation expense	1919.59	1792.60	1608.57	3712.19	2833.91	6072.94
	(f) Other expenses	3678.5	3056.30	2163.85	6734.80	4304.92	11018.76
	Total Expenses	44347.13	35171.45	25139.61	79518.58	43008.81	113753.85
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	5179.67	4245.40	4125.44	9425.07	7377.36	17556.75
4.	Other Income	412.71	411.99	450.57	824.70	450.65	1289.40
5.	Profit before finance costs and exceptional Items (3+4)	5592.38	4657.39	4576.01	10249.77	7828.01	18846.15
6.	Finance costs	2767.91	2492.77	2107.77	5260.68	4068.13	10299.51
7.	Profit after finance costs but before exceptional Items (5-6)	2824.47	2164.62	2468.24	4989.09	3759.88	8546.64
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2824.47	2164.62	2468.24	4989.09	3759.88	8546.64
10.	Tax Expense	569.53	561.85	328.94	1131.38	507.60	1221.64
11.	Net Profit from ordinary activities after tax (9-10)	2254.94	1602.77	2139.30	3857.71	3252.28	7325.00
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	2254.94	1602.77	2139.30	3857.71	3252.28	7325.00
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	76,212.05
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	1.01	0.71	0.95	1.72	1.45	3.27
	b) Diluted	1.01	0.71	0.95	1.72	1.45	3.27
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	1.01	0.71	0.95	1.72	1.45	3.27
	b) Diluted	1.01	0.71	0.95	1.72	1.45	3.27

Part II Select Information for the Quarter and six month ended 30.09.2012

A							
Particulars of shareholding							
1.	Public Shareholding						
	- Number of Shares	12,47,92,970	12,47,92,970	12,48,96,970	12,47,92,970	12,48,96,970	12,47,92,970
	- Percentage of Shareholding	55.65	55.65	55.69	55.65	55.69	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	9,94,68,000	9,94,68,000	9,93,64,000	9,94,68,000	9,93,64,000	9,94,68,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.31	44.35	44.31	44.35
B Investor Complaints		3 Months ended 30.09.2012					
	Pending at the beginning of Quarter	-					
	Received During the Quarter	15					
	Disposed Off During the Quarter	15					
	Pending at the end of Quarter	-					

Statement of Assets and Liabilities		(Rs in Lacs)	
PARTICULARS	As at 30.09.2012	As at 31.03.2012	
	Unaudited	Audited	
SHAREHOLDERS' FUND			
(I) Capital	2,242.61	2,242.61	
(ii) Reserves and Surplus	80,069.76	76,212.05	
NON CURRENT LIABILITIES			
(i) Long Term Liabilities	32,909.64	36,361.74	
(ii) Deffered Tax Liability	7,433.59	6,302.21	
(ii) Other Long Term Liabilities	194.15	195.68	
(iii) Long Term Provisions	368.45	342.63	
CURRENT LIABILITIES			
(i) Short Term Borrowings	51,629.76	56,521.15	
(ii) Trade Payables	36,468.19	19,449.11	
(iii) Other Current Liabilities	15,548.80	12,984.30	
(iv) Short Term Provisions	2,229.38	1,481.37	
	2,29,094.33	2,12,092.85	
NON CURRENT ASSETS			
(i) Fixed Assets (Incl CWIP)	1,04,810.72	1,00,800.54	
(ii) Non Current Investments	5.01	5.01	
(iii) Long Term Loans & Advances	7,414.98	6,318.50	
(iv) Other Non Current Assets	1.88	2.25	
CURRENT ASSETS			
(i) Current Investments	34.11	14.11	
(ii) Inventories	60,095.40	59,141.59	
(iii) Trade Receivables	37,203.71	30,449.27	
(iv) Cash & Bank Balances	431.37	2,592.48	
(v) Short Term Loans & Advances	15,960.98	10,504.17	
(vi) Other Current Assets	3,136.17	2,264.93	
	2,29,094.33	2,12,092.85	
Notes:			
1 The above financial results were reviewed by Audit Committee on 01.11.12 and approved by the Board in its meeting held on even date i.e. 01.11.12 and further limited reviewed by the Statutory Auditors of the Company.			
2 The company is exclusively in the pharmaceutical business segment.			
3 The Shareholders in their Annual General Meeting held on 29.09.2012 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2011-12. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement facility of RBI.			
4 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.			
5 The above financial results are on stand alone basis.			
			By Order of the Board of Directors of Nectar Lifesciences Limited sd/- (Sanjiv Goyal) Chairman & Managing Director
Dated: 01.11.2012			
Place: Chandigarh			